Not So Different: A Podcast from The Center for Biosimilars

S6 Ep19: Biosimilar Business Roundup for October 2023—Podcast Edition

Listen

Description


FDA Approves First Subcutaneous Infliximab Product



Abrilada Approved as Second Interchangeable Humira Biosimilar



Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future



Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart



Eye on Pharma: Another CRL for Alvotech; Cimerli’s Growing Market Share; BBCIC Awarded Grant



Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate



AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry